Jump to navigation Jump to search
Clinical data
Routes of
ATC code
Pharmacokinetic data
Protein binding7%
Elimination half-life8 hours
ExcretionRenal, unchanged
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Molar mass180.247 g/mol

WikiDoc Resources for Rilmenidine


Most recent articles on Rilmenidine

Most cited articles on Rilmenidine

Review articles on Rilmenidine

Articles on Rilmenidine in N Eng J Med, Lancet, BMJ


Powerpoint slides on Rilmenidine

Images of Rilmenidine

Photos of Rilmenidine

Podcasts & MP3s on Rilmenidine

Videos on Rilmenidine

Evidence Based Medicine

Cochrane Collaboration on Rilmenidine

Bandolier on Rilmenidine

TRIP on Rilmenidine

Clinical Trials

Ongoing Trials on Rilmenidine at Clinical

Trial results on Rilmenidine

Clinical Trials on Rilmenidine at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Rilmenidine

NICE Guidance on Rilmenidine


FDA on Rilmenidine

CDC on Rilmenidine


Books on Rilmenidine


Rilmenidine in the news

Be alerted to news on Rilmenidine

News trends on Rilmenidine


Blogs on Rilmenidine


Definitions of Rilmenidine

Patient Resources / Community

Patient resources on Rilmenidine

Discussion groups on Rilmenidine

Patient Handouts on Rilmenidine

Directions to Hospitals Treating Rilmenidine

Risk calculators and risk factors for Rilmenidine

Healthcare Provider Resources

Symptoms of Rilmenidine

Causes & Risk Factors for Rilmenidine

Diagnostic studies for Rilmenidine

Treatment of Rilmenidine

Continuing Medical Education (CME)

CME Programs on Rilmenidine


Rilmenidine en Espanol

Rilmenidine en Francais


Rilmenidine in the Marketplace

Patents on Rilmenidine

Experimental / Informatics

List of terms related to Rilmenidine

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Rilmenidine is a prescription medication administered to treat hypertension. It is marketed under the brand name HYPERIUM®.

Form and Composition

Each tablet contains 1.544 mg rilmenidine dihydrogen phosphate, an amount equivalent to 1 mg rilmenidine base.


Hyperium, an oxazoline compound with antihypertensive properties, acts on both medullary and peripheral vasomotor structures. Hyperium shows greater selectivity for imidazoline receptors than for cerebral alpha2-adrenergic receptors, distinguishing it from reference alpha2-agonists.




Severe depression, severe renal failure (creatinine clearance <15 ml/min), as a precaution in the absence of currently available studies.


Therapy should never be interrupted suddenly; the dosage should be reduced gradually.


  • As with all antihypertensive agents, regular medical monitoring is required when Hyperium is administered to patients with a recent history of cardiovascular disease (stroke, myocardial infarction).
  • Alcohol consumption should be avoided during treatment.
  • In patients with renal failure, no dosage adjustment is necessary if creatinine clearance is greater than 15 mL/min.
  • In the absence of documented experiments in this area, Hyperium is not recommended for prescription to children.
  • Pregnancy: as with all new molecules, administration of Hyperium should be avoided in pregnant women, although no teratogenic or embryotoxic effects have been observed in animal studies.
  • Lactation: Hyperium is excreted in breast milk, and its use is therefore not recommended during lactation.
  • Effects on the ability to drive motor vehicles or operate machinery: double-blind, placebo-controlled studies have not shown Hyperium to have any effect on alertness at therapeutic doses (1or 2 daily administrations of 1 mg). If these doses are exceeded, or if Hyperium is combined with other drugs capable of reducing alertness, vehicle drivers or machine operators should be warned of the possibility of drowsiness.

Drug interactions

Combinations not recommended: combination with MAOIs is not recommended; combination with tricyclic antidepressants requires prudence, as the antihypertensive activity of Hyperium may be partly antagonized.

Side Effects

  • At a dose of 1 mg given as a single daily administration during controlled trials, the incidence of side effects was comparable to that observed with placebo.
  • At a dose of 2 mg per day of Hyperium, controlled comparative studies versus clonidine (0.15 to 0.30 mg/day) or alpha2-methyldopa (500 to 1000 mg/day) demonstrated that the incidence of side effects was significantly lower with Hyperium than with either clonidine or a-methyldopa.

Side-effects are rare, non-severe, and transient at therapeutic doses: asthenia, palpitations, insomnia, drowsiness, fatigue on exercise, epigastric pain, dryness of the mouth, diarrhea, skin rash; and exceptionally, cold extremities, postural hypotension, sexual disorders, anxiety, depression, pruritus, edema, cramps, nausea, constipation, hot flushes.

Dosage and Route of Administration

The recommended dosage is 1 tablet per day as a single morning administration. If results are not adequate after 1 month of treatment, the dosage may be increased to 2 tablets per day, given in divided doses (1 tablet morning and evening) before meals. As a result of its good clinical and biological acceptability, Hyperium may be administered to both elderly and diabetic hypertensive patients. In patients with renal failure, no dosage adjustment is necessary in principle when the creatinine clearance is greater than 15 mL/min.

Treatment may be continued indefinitely.


No cases of massive absorption have been reported. Likely symptoms in such an eventuality would be marked hypotension and lowered alertness. In addition to gastric lavage, sympathomimetic agents may also required. Hyperium is only slightly dialysable.